Onyx Scientific, a leading CDMO in the small molecule space, has completed the second phase of expansion at its state-of-the-art Chemistry, Manufacturing and Controls (CMC) facility in Sunderland, UK. The investment increases the facility’s capabilities to support its customers in CMC services and adds further strength to Onyx’s UK manufacturing capabilities for non-GMP scale-up by more than 50%. Onyx first opened its state-of-the-art CMC GMP facility in 2022, doubling the company’s footprint and allowing for expansion of all CMC services, including the introduction of additional GMP facilities that increased capacity for clinical and commercial API manufacturing by 50%.